Second primary malignancy among older adults with multiple myeloma receiving first-line lenalidomide-based therapy: A population-based analysis.

Journal of Geriatric Oncology
Smith GiriAdam J Olszewski

Abstract

Clinical trials have suggested that patients with myeloma treated with lenalidomide may have an increased risk of second primary malignancies (SPM). Whether such risks are of significant relevance in the real-world clinical practice, particularly among older patients receiving first-line lenalidomide based therapy, remains unclear. Using Surveillance Epidemiology and End Results-Medicare database, we identified adults ≥ 65 years with plasma cell myeloma diagnosed in 2007-2015 who received at least one oral anti-myeloma agent. We defined first-line lenalidomide-containing therapy as use within 90 days of diagnosis. SPM was defined as a malignancy reported to a cancer registry > 90 days after myeloma diagnosis. We computed cumulative incidence of SPM (with death being a competing event) and compared SPM rates between patients treated with or without first-line lenalidomide using a Fine-Gray's model, adjusting for age, sex, race, ethnicity, prior malignancy, and histologic subtype. Of 9850 Medicare beneficiaries, 4009 (41%) received first-line lenalidomide. During median follow up of 5.0 years, 423 patients (4.3%) developed SPM, including 361 solid tumors (85%) and 61 hematologic malignancies (14%). The cumulative incidence of any...Continue Reading

References

Dec 17, 2008·Hematology·Brad Kahl, David Yang
Feb 9, 2012·Blood·Anish ThomasOla Landgren
May 11, 2012·The New England Journal of Medicine·Antonio PalumboUNKNOWN MM-015 Investigators
May 11, 2012·The New England Journal of Medicine·Philip L McCarthyCharles Linker
May 11, 2012·The New England Journal of Medicine·Michel AttalUNKNOWN IFM Investigators
Oct 18, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Amrita Y KrishnanSmita Bhatia
Apr 10, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joan L WarrenGregory A Abel
Feb 26, 2016·Scientific Reports·Tianhui ChenUNKNOWN GEKID Cancer Survival Working Group
Nov 20, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P MustoUNKNOWN International Myeloma Working Group
May 26, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Adam J OlszewskiAmal N Trivedi
Jul 26, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip L McCarthyMichel Attal
Jul 6, 2018·British Journal of Haematology·Luciano J CostaSmita Bhatia
Aug 17, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Adam J OlszewskiAmy J Davidoff

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Disparities

Cancer disparities refers to differences in cancer outcomes (e.g., number of cancer cases, related health complications) across population groups.